122 related articles for article (PubMed ID: 37589161)
1. Accelerated loss of lean body mass in head and neck cancer patients during cisplatin-based chemoradiation.
Lønbro S; Gam S; Hermann AP; Hansen CR; Johansen J
Acta Oncol; 2023 Nov; 62(11):1403-1411. PubMed ID: 37589161
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Chemoradiotherapy Induces Body Composition Changes in Locally Advanced Head and Neck Squamous Cell Carcinoma: Comparison between Oral Cavity and Non-Oral Cavity Cancer.
Lin YC; Ling HH; Chang PH; Pan YP; Wang CH; Chou WC; Chen FP; Yeh KY
Nutrients; 2021 Aug; 13(9):. PubMed ID: 34578846
[TBL] [Abstract][Full Text] [Related]
3. Progressive resistance training in head and neck cancer patients during concomitant chemoradiotherapy -- design of the DAHANCA 31 randomized trial.
Lonkvist CK; Lønbro S; Vinther A; Zerahn B; Rosenbom E; Primdahl H; Hojman P; Gehl J
BMC Cancer; 2017 Jun; 17(1):400. PubMed ID: 28578654
[TBL] [Abstract][Full Text] [Related]
4. Characterization of changes in total body composition for patients with head and neck cancer undergoing chemoradiotherapy using dual-energy x-ray absorptiometry.
Jackson W; Alexander N; Schipper M; Fig L; Feng F; Jolly S
Head Neck; 2014 Sep; 36(9):1356-62. PubMed ID: 23970480
[TBL] [Abstract][Full Text] [Related]
5. Lean body mass and muscle function in head and neck cancer patients and healthy individuals--results from the DAHANCA 25 study.
Lønbro S; Dalgas U; Primdahl H; Johansen J; Nielsen JL; Overgaard J; Overgaard K
Acta Oncol; 2013 Oct; 52(7):1543-51. PubMed ID: 23964657
[TBL] [Abstract][Full Text] [Related]
6. Changes in body mass, energy balance, physical function, and inflammatory state in patients with locally advanced head and neck cancer treated with concurrent chemoradiation after low-dose induction chemotherapy.
Silver HJ; Dietrich MS; Murphy BA
Head Neck; 2007 Oct; 29(10):893-900. PubMed ID: 17405169
[TBL] [Abstract][Full Text] [Related]
7. Progressive resistance training rebuilds lean body mass in head and neck cancer patients after radiotherapy--results from the randomized DAHANCA 25B trial.
Lønbro S; Dalgas U; Primdahl H; Johansen J; Nielsen JL; Aagaard P; Hermann AP; Overgaard J; Overgaard K
Radiother Oncol; 2013 Aug; 108(2):314-9. PubMed ID: 23932192
[TBL] [Abstract][Full Text] [Related]
8. Prospective randomized trial to compare accelerated (six fractions a week) radiotherapy against concurrent chemoradiotherapy (using conventional fractionation) in locally advanced head and neck cancers.
Gupta M; Mahajan R; Kaushal V; Seem RK; Gupta M; Bhattacharyya T
J Cancer Res Ther; 2015; 11(4):723-9. PubMed ID: 26881508
[TBL] [Abstract][Full Text] [Related]
9. Treatment Tolerance of Cetuximab versus Alternative Chemotherapy Agents in Non-Cisplatin Candidates with Head and Neck Cancer Receiving Concurrent Chemoradiotherapy.
Morse RT; Ganju RG; Neeranjun R; Gan GN; Cao Y; Neupane P; Kakarala K; Shnayder Y; Lominska CE
Chemotherapy; 2023; 68(1):35-43. PubMed ID: 35882207
[TBL] [Abstract][Full Text] [Related]
10. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
[TBL] [Abstract][Full Text] [Related]
11. Progressive resistance training in head and neck cancer patients undergoing concomitant chemoradiotherapy.
Lonkvist CK; Vinther A; Zerahn B; Rosenbom E; Deshmukh AS; Hojman P; Gehl J
Laryngoscope Investig Otolaryngol; 2017 Oct; 2(5):295-306. PubMed ID: 29094074
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and efficacy of progressive resistance training and dietary supplements in radiotherapy treated head and neck cancer patients--the DAHANCA 25A study.
Lønbro S; Dalgas U; Primdahl H; Overgaard J; Overgaard K
Acta Oncol; 2013 Feb; 52(2):310-8. PubMed ID: 23190359
[TBL] [Abstract][Full Text] [Related]
13. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and toxicity of concurrent chemoradiation for elderly patients with head and neck cancer.
Daly ME; Lau DH; Farwell DG; Luu Q; Donald PJ; Chen AM
Am J Otolaryngol; 2013; 34(6):631-5. PubMed ID: 23954137
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis.
Vanderveken OM; Szturz P; Specenier P; Merlano MC; Benasso M; Van Gestel D; Wouters K; Van Laer C; Van den Weyngaert D; Peeters M; Vermorken J
Oncologist; 2016 Jan; 21(1):59-71. PubMed ID: 26712958
[TBL] [Abstract][Full Text] [Related]
16. Changes in lean and skeletal muscle body mass in adult females with anorexia nervosa before and after weight restoration.
El Ghoch M; Pourhassan M; Milanese C; Müller MJ; Calugi S; Bazzani PV; Dalle Grave R
Clin Nutr; 2017 Feb; 36(1):170-178. PubMed ID: 26560758
[TBL] [Abstract][Full Text] [Related]
17. Post hoc analysis of a randomized controlled trial comparing concurrent chemoradiation with cisplatin versus nimotuzumab-cisplatin, focusing on acute oral mucositis.
Noronha V; Patil VM; Singh GK; Joshi A; Menon N; Lashkar SG; Mathrudev V; Satam KN; Prabhash K
J Egypt Natl Canc Inst; 2021 May; 33(1):12. PubMed ID: 34021843
[TBL] [Abstract][Full Text] [Related]
18. Disease-induced and treatment-induced alterations in body composition in locally advanced head and neck squamous cell carcinoma.
Willemsen ACH; Hoeben A; Lalisang RI; Van Helvoort A; Wesseling FWR; Hoebers F; Baijens LWJ; Schols AMWJ
J Cachexia Sarcopenia Muscle; 2020 Feb; 11(1):145-159. PubMed ID: 31536685
[TBL] [Abstract][Full Text] [Related]
19. Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis.
Lee SY; Choi YS; Song IC; Park SG; Keam B; Yang YJ; Song EK; Lee HJ; Cho SH; Shim H; Park KU; Lee KH; Jo DY; Jo IS; Yun HJ;
Medicine (Baltimore); 2018 May; 97(21):e10778. PubMed ID: 29794758
[TBL] [Abstract][Full Text] [Related]
20. DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity.
Saksø M; Jensen K; Andersen M; Hansen CR; Eriksen JG; Overgaard J
Radiother Oncol; 2020 Jul; 148():65-72. PubMed ID: 32335364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
